This is somewhat illustrated by results from our model, which underscore the decisive influence of osteocytes and the potential for sclerostin-targeted treatments to reduce bone loss in pathologic conditions ranging from osteoporosis to osteolytic cancers. Here, SOST is linked to osteoporosis.